PolyActiva Pty Ltd

Based in Australia, PolyActiva Pty Ltd develops innovative biodegradable implants that deliver sustained drug release, focusing on improving treatment outcomes for patients with ophthalmic diseases, particularly glaucoma. PolyActiva Pty Ltd, founded in 2010 and headquartered in Melbourne, Australia, specializes in biodegradable drug delivery systems. The CEO, Russell Tait, leads the company, which has successfully completed 4 deals, with the most recent funding round being a Series C on 30 May 2025. This round raised AUD 40 million, led by the National Reconstruction Fund Corporation, with participation from Brandon Capital Partners.

The total amount raised to date is AUD 40 million. PolyActiva specializes in developing biodegradable implants designed for sustained drug release, primarily targeting patients with ophthalmic diseases like glaucoma. Their flagship product, PA5108, utilizes the proprietary Prezia Sustained Drug Delivery Technology platform, aimed at enhancing patient outcomes. The company's research is focused on addressing the clinical need for effective ophthalmology treatments, and their products are intended for healthcare providers, ophthalmologists, and patients requiring long-term management of ocular conditions.

PolyActiva's revenue model is centered around partnerships and collaborations in the biopharmaceutical industry, primarily engaging in B2B transactions with healthcare institutions. The company forms strategic alliances to distribute and integrate its drug delivery systems into clinical practices, enhancing patient care through agreements with hospitals and specialty clinics. The pricing structures are negotiated based on the value of their technology, reflecting its efficacy. Their recent AUD 40 million Series C funding round indicates a commitment to scaling operations and advancing their product pipeline, expected to positively influence future revenue streams.

PolyActiva plans to utilize the AUD 40 million raised in the Series C funding round, led by the National Reconstruction Fund Corporation, to advance the clinical development of its lead ocular implant candidate, PA5108, which delivers latanoprost. The company aims to expand its market presence globally, particularly in regions with high incidences of ocular diseases. This expansion is focused on increasing access to their innovative medical solutions and is anticipated to continue throughout 2025 as they work to finalize product development and secure additional partnerships.